Chinese Biosimilar Boom Is Heralded By First Approval
Executive Summary
Approval of China's first rituximab biosimilar under new pathway gives developers much-needed boost and an opening to the international market for made-in-China biosimilars helped by favorable regulatory policy changes at home.
You may also be interested in...
FDA Begins Reviewing Henlius’ Trastuzumab
The US FDA has accepted a BLA for Henlius’ trastuzumab biosimilar candidate HLX02, marking another step in the Chinese company’s push for the US oncology market
Henlius Delivers On Innovation Agenda In 2021
Henlius has focused its efforts on becoming a fully-fledged biopharmaceutical company during 2021, moving away from its roots as a biosimilar drug company.
Henlius Wins Chinese Approval For Rituximab RA Indication
Henlius says it can now pursue a “differentiated strategy” for its HLX01 rituximab biosimilar in China, after winning approval for a key rheumatoid arthritis indication from the NMPA.